Multiple Myeloma Market Size & Share, by Drug Class (Proteasome Inhibitors, Immunomodulatory Drugs, Steroids, Monoclonal Antibodies); Therapy (Immunotherapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant); Distribution Channel (Hospital, Retail, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2898
  • Published Date: Sep 04, 2023
  • Report Format: PDF, PPT

Companies Dominating the Multiple Myeloma Landscape

    • Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amgen Inc.
    • Johnson & Johnson
    • Novartis AG
    • Sanofi
    • Janssen Pharmaceuticals Inc.
    • Genentech, Inc.
    • AbbVie Inc.
    • Karyopharm

Browse Key Market Insights with Data Illustration:


In The News

  • Abecma, a B-cell maturation antigen-directed CAR T cell immunotherapy, has been approved for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, according to a statement from the pharmaceutical company Bristol-Myers Squibb.
  • The FDA has approved Johnson and Johnson's drug TECVAYLI, which is used to treat people with multiple myeloma that has relapsed or become resistant to treatment.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2898
  • Published Date: Sep 04, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing incidences of multiple myeloma, growing number of product unveilings and increase in the initiatives taken by the government are driving the market growth.

The market size of multiple myeloma is anticipated to attain a CAGR of 15% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Daiichi Sankyo Company Limited, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company and others.

The immunomodulatory drugs segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying